ReviewJournal of clinical medicine2020
The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Esophageal and Oropharyngeal Dysphagia: Clinical Recommendations From the United European Gastroenterology and European Society for Neurogastroenterology and Motility.United European gastroenterology journal · 2025Guideline
- British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.Rheumatology (Oxford, England) · 2022Guideline
- Association between Oropharyngeal Dysphagia and Subgroups of Patients with Idiopathic Inflammatory Myopathy: A Cross-Sectional Study.Dysphagia · 2026Article
- Association of malnutrition with in-hospital outcomes among patients hospitalized with dermatomyositis or polymyositis.Clinical rheumatology · 2026Article
- Article
- Review
- Systemic lupus erythematosus is associated with an increased risk for orthorexia nervosa: a cross-sectional study.Rheumatology international · 2026Article
- Mapping neurogenic dysphagia diagnostics in Germany: accessibility, implementation practices, and barriers to swallowing endoscopy.Neurological research and practice · 2026Article
- Impact of a Neurogenic Dysphagia Outpatient Clinic on Diagnosis, Treatment, and Nutrition.European journal of neurology · 2026Article
- Increased severity and relapse rate in adult anti-nuclear matrix protein 2 antibody positive myositis patients with distal limb weakness: a retrospective study in China.Frontiers in medicine · 2026Article
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- Aquaporin-4 downregulation in dysphagic patients with idiopathic inflammatory myopathies: myofiber vulnerability and inflammation drivers.Rheumatology (Oxford, England) · 2025Article
- Utilization of Rehabilitation Services After Idiopathic Inflammatory Myopathy Diagnosis: A Retrospective Cohort Assessment in the United States.The Journal of rheumatology · 2025Article
- Classifying neurogenic dysphagia as a movement disorder.Brain : a journal of neurology · 2025Review
- Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study.Rheumatology and therapy · 2025Article
- Frequency of dysphagia among patients submitted to a rheumatology department: a cross-sectional analysis based on the EAT-10 questionnaire.Rheumatology international · 2025Article
- Comorbidities and their impact on in-hospital mortality in hospitalized adult patients with bacterial community-acquired pneumonia: a cohort study.Journal of thoracic disease · 2025Article
- Esophageal Dysfunction in Immune Checkpoint Inhibitor-related Myositis.Internal medicine (Tokyo, Japan) · 2025Article
- A Retrospective Review of Clinical Characteristics and Risk Factors of Dysphagia in Patients with Dermatomyositis.Dysphagia · 2025Article
- Muscle weakness with a hidden cause.BMJ case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Dysphagia is a clinical hallmark and part of the current American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) diagnostic criteria for idiopathic inflammatory myopathy (IIM). However, the data on dysphagia in IIM are heterogenous and partly conflicting. The aim of this study was to conduct a systematic review on epidemiology, pathophysiology, outcome and therapy and a meta-analysis on the prevalence of dysphagia in IIM. (2) Methods: Medline was systematically searched for all relevant articles. A random effect model was chosen to estimate the pooled prevalence of dysphagia in the overall cohort of patients with IIM and in different subgroups. (3) Results: 234 studies were included in the review and 116 (10,382 subjects) in the meta-analysis. Dysphagia can occur as initial or sole symptom. The overall pooled prevalence estimate in IIM was 36% and with 56% particularly high in inclusion body myositis. The prevalence estimate was significantly higher in patients with cancer-associated myositis and with NXP2 autoantibodies. Dysphagia is caused by inflammatory involvement of the swallowing muscles, which can lead to reduced pharyngeal contractility, cricopharyngeal dysfunction, reduced laryngeal elevation and hypomotility of the esophagus. Swallowing disorders not only impair the quality of life but can lead to serious complications such as aspiration pneumonia, thus increasing mortality. Beneficial treatment approaches reported include immunomodulatory therapy, the treatment of associated malignant diseases or interventional procedures targeting the cricopharyngeal muscle such as myotomy, dilatation or botulinum toxin injections. (4) Conclusion: Dysphagia should be included as a therapeutic target, especially in the outlined high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.